Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

NCT01596400 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy Induced Nausea and Vomiting

Interventions

DRUG: granisetron transdermal system
DRUG: Granisetron IV

Sponsor

Kyowa Kirin Pharmaceutical Development Ltd